🚀 VC round data is live in beta, check it out!
Nexstim Valuation Multiples
Discover revenue and EBITDA valuation multiples for Nexstim and similar public comparables like Applied BioCode, Meditera, Medicalgorithmics, Sensus Healthcare and more.
Nexstim Overview
About Nexstim
Nexstim Oyj is medical technology company. The company has developed a non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with 3D navigation providing accurate and personalized targeting of TMS to the specific area of the brain. The company earns revenue from Finland, Rest of Europe, North America and Other. The majority of revenue is earned in North America.
Founded
2000
HQ
Employees
40
Website
Sectors
Financials (LTM)
EV
$79M
Nexstim Financials
Nexstim reported last 12-month revenue of $13M and EBITDA of $2M.
In the same LTM period, Nexstim generated $2M in EBITDA.
Revenue (LTM)
Nexstim P&L
In the most recent fiscal year, Nexstim reported revenue of $13M and EBITDA of $2M.
Nexstim expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $13M | XXX | $13M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $12M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 90% | XXX | XXX | XXX |
| EBITDA | $2M | XXX | $2M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | — | XXX | $675K | XXX | XXX | XXX |
| Net Margin | — | XXX | 5% | XXX | XXX | XXX |
| Net Debt | — | — | $2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Nexstim Stock Performance
Nexstim has current market cap of $77M, and enterprise value of $79M.
Market Cap Evolution
Nexstim's stock price is $10.70.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $79M | $77M | 0.0% | XXX | XXX | XXX | $0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNexstim Valuation Multiples
Nexstim trades at 5.9x EV/Revenue multiple, and 34.7x EV/EBITDA.
EV / Revenue (LTM)
Nexstim Financial Valuation Multiples
As of April 20, 2026, Nexstim has market cap of $77M and EV of $79M.
Equity research analysts estimate Nexstim's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nexstim has a P/E ratio of 114.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $77M | XXX | $77M | XXX | XXX | XXX |
| EV (current) | $79M | XXX | $79M | XXX | XXX | XXX |
| EV/Revenue | 5.9x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBITDA | 34.7x | XXX | 36.6x | XXX | XXX | XXX |
| EV/EBIT | 83.0x | XXX | 105.3x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 6.8x | XXX | XXX | XXX |
| P/E | — | XXX | 114.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1794.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nexstim Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Nexstim Margins & Growth Rates
Nexstim's revenue in the last 12 month grew by 20%.
Nexstim's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
Nexstim's rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nexstim's rule of X is 60% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Nexstim Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 47% | XXX | 35% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 60% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 84% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Nexstim Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nexstim | XXX | XXX | XXX | XXX | XXX | XXX |
| Applied BioCode | XXX | XXX | XXX | XXX | XXX | XXX |
| Meditera | XXX | XXX | XXX | XXX | XXX | XXX |
| Medicalgorithmics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sensus Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| FluoGuide | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nexstim M&A Activity
Nexstim acquired XXX companies to date.
Last acquisition by Nexstim was on XXXXXXXX, XXXXX. Nexstim acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Nexstim
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNexstim Investment Activity
Nexstim invested in XXX companies to date.
Nexstim made its latest investment on XXXXXXXX, XXXXX. Nexstim invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Nexstim
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nexstim
| When was Nexstim founded? | Nexstim was founded in 2000. |
| Where is Nexstim headquartered? | Nexstim is headquartered in Finland. |
| How many employees does Nexstim have? | As of today, Nexstim has over 40 employees. |
| Is Nexstim publicly listed? | Yes, Nexstim is a public company listed on Nasdaq Helsinki. |
| What is the stock symbol of Nexstim? | Nexstim trades under NXTMH ticker. |
| When did Nexstim go public? | Nexstim went public in 2014. |
| Who are competitors of Nexstim? | Nexstim main competitors are Applied BioCode, Meditera, Medicalgorithmics, Sensus Healthcare. |
| What is the current market cap of Nexstim? | Nexstim's current market cap is $77M. |
| What is the current revenue of Nexstim? | Nexstim's last 12 months revenue is $13M. |
| What is the current revenue growth of Nexstim? | Nexstim revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Nexstim? | Current revenue multiple of Nexstim is 5.9x. |
| Is Nexstim profitable? | Yes, Nexstim is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nexstim? | Nexstim's last 12 months EBITDA is $2M. |
| What is Nexstim's EBITDA margin? | Nexstim's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Nexstim? | Current EBITDA multiple of Nexstim is 34.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.